xisomab 3g3
mAbexperimental
Clinical trial activity
3 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jun 1, 2017 (NCT03097341)
Timeline
Indications
Mechanism of action
- Coagulation factor XIINHIBITOR
F11 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- xisomab 3g3
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04465760 | Phase 2 | Nov 15, 2020 | National Heart, Lung, and Blood Institute (NHLBI), OHSU Knight Cancer Institute, Oregon Health and Science University |
| NCT03612856 | Phase 2 | Oct 31, 2018 | Aronora, Inc. |
| NCT03097341 | Phase 1 | Jun 1, 2017 | Aronora, Inc. |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Aronora, Inc. | For profit | 2 | 2 | 2 | 2017 |
| National Heart, Lung, and Blood Institute (NHLBI) | Government | 1 | 0 | 1 | 2020 |
| OHSU Knight Cancer Institute | Academic/Hospital | 1 | 1 | 1 | 2020 |
| Oregon Health and Science University | Academic/Hospital | 1 | 0 | 1 | 2020 |
4 organizations
Page 1 / 1